Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma, Extranodal NK-T-Cell 2 TMB-H 1 Recurrence 1 Neoplasm Metastasis 1 Melanoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Large B-Cell, Diffuse 1 Liver Neoplasms 1 Gallbladder Neoplasms 1 Cholangiocarcinoma 1 Biliary Tract Neoplasms 1

Interventions

Sorafenib 61 Bevacizumab 42 Oxaliplatin 24 Doxorubicin 22 Radiosurgery 20 Gemcitabine 20 Fluorouracil 20 Nivolumab 19 durvalumab 18 Radiofrequency Ablation 18 pembrolizumab 17 Capecitabine 17 lenvatinib 16 Cisplatin 16 atezolizumab 13 Leucovorin 13 Radiotherapy 11 tremelimumab 10 Cyclophosphamide 10 Carboplatin 10 Irinotecan 9 Ipilimumab 9 Drug Therapy 9 Everolimus 8 Cryosurgery 8 toripalimab 7 fludarabine 7 Sunitinib 7 Chemotherapy, Adjuvant 7 Melphalan 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Liver Neoplasms × IMC-001 × Clear all

NCT04196465 2026-05-22

NeoChance

Asan Medical Center

Phase 2 Active not recruiting

Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡